165 related articles for article (PubMed ID: 12508552)
21. [Clinical evaluation of urinary NMP22 (nuclear matrix protein 22) bladder chek in the detection of patients with bladder cancer].
Kitsukawa S; Yamamoto Y; Hosoda S; Otsuru N; Matsumoto T; Matsumoto T; Aizawa T; Noda K; Ito T
Hinyokika Kiyo; 2006 Mar; 52(3):167-72. PubMed ID: 16617867
[TBL] [Abstract][Full Text] [Related]
22. Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma.
Todenhöfer T; Hennenlotter J; Tews V; Gakis G; Aufderklamm S; Kuehs U; Stenzl A; Schwentner C
Urol Oncol; 2013 Oct; 31(7):1148-54. PubMed ID: 22130125
[TBL] [Abstract][Full Text] [Related]
23. The clinical utility of atypical cytology is significantly increased in both screening and monitoring for bladder cancer when indexed with nuclear matrix protein-22.
Raina R; Pahlajani G; Ponsky LE; Agarwal A; Zippe CD
BJU Int; 2008 Aug; 102(3):297-300. PubMed ID: 18702780
[TBL] [Abstract][Full Text] [Related]
24. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.
Hutterer GC; Karakiewicz PI; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Serretta V; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Perrotte P; Lotan Y; Marberger MJ; Shariat SF
BJU Int; 2008 Mar; 101(5):561-5. PubMed ID: 18257856
[TBL] [Abstract][Full Text] [Related]
25. Urinary nuclear matrix protein 22 for diagnosis of renal cell carcinoma.
Kaya K; Ayan S; Gokce G; Kilicarslan H; Yildiz E; Gultekin EY
Scand J Urol Nephrol; 2005; 39(1):25-9. PubMed ID: 15764267
[TBL] [Abstract][Full Text] [Related]
26. [The study of relationship between nuclear metrix protein 22 urinary level and the grade and stage of bladder transitional cell carcinoma].
Xin DQ; You R; Ding Y; Liu LQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2006 May; 44(10):681-3. PubMed ID: 16784679
[TBL] [Abstract][Full Text] [Related]
27. Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder.
Watson JA; Burling K; Fitzpatrick P; Kay E; Kelly J; Fitzpatrick JM; Dervan PA; McCann A
BJU Int; 2009 Mar; 103(5):694-7. PubMed ID: 19040529
[TBL] [Abstract][Full Text] [Related]
28. [Clinical evaluation of urinary nuclear matrix protein 22 as a marker for bladder cancer].
Kurokawa S; Morita T; Muraishi O; Tokue A
Hinyokika Kiyo; 2001 Apr; 47(4):247-50. PubMed ID: 11411098
[TBL] [Abstract][Full Text] [Related]
29. [Significance and application of nuclear matrix protein 22 in detecting bladder cancer].
Liu GH; Li HZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Dec; 23(6):654-6. PubMed ID: 12901118
[TBL] [Abstract][Full Text] [Related]
30. [Screening methods in the detection of bladder cancer: comparison of nuclear matrix protein-22, bladder tumor antigen and cytological examinations].
Fukui Y; Samma S; Fujimoto K; Akiyama T; Yamaguchi A; Hirayama A
Hinyokika Kiyo; 2001 May; 47(5):311-4. PubMed ID: 11433750
[TBL] [Abstract][Full Text] [Related]
31. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma.
Hakenberg OW; Fuessel S; Richter K; Froehner M; Oehlschlaeger S; Rathert P; Meye A; Wirth MP
Urology; 2004 Dec; 64(6):1121-6. PubMed ID: 15596183
[TBL] [Abstract][Full Text] [Related]
32. [Urinary NMP22 as a new marker in patients with transitional cell carcinoma].
Muzzonigro G; Minardi D; Galosi AB; Recchioni A; De Sio G; Polito M
Arch Ital Urol Androl; 1999 Jun; 71(3):171-7. PubMed ID: 10431409
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic value of the nuclear matrix protein 22 test and urine cytology in upper tract urothelial tumors.
Jovanovic M; Soldatovic I; Janjic A; Vuksanovic A; Dzamic Z; Acimovic M; Hadzi-Djokic J
Urol Int; 2011; 87(2):134-7. PubMed ID: 21865670
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer.
Chang YH; Wu CH; Lee YL; Huang PH; Kao YL; Shiau MY
Urology; 2004 Oct; 64(4):687-92. PubMed ID: 15491702
[TBL] [Abstract][Full Text] [Related]
35. [Availability of NMP22 (nuclear matrix protein 22) for the diagnosis of urothelial cancer].
Akagashi K; Tanda H; Kato S; Ohnishi S; Nakajima H; Nanbu A; Nitta T; Koroku M
Hinyokika Kiyo; 2001 May; 47(5):307-10. PubMed ID: 11433749
[TBL] [Abstract][Full Text] [Related]
36. Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder.
Gupta NP; Sharma N; Kumar R
Urology; 2009 Mar; 73(3):592-6; discussion 596-7. PubMed ID: 19168205
[TBL] [Abstract][Full Text] [Related]
37. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
Shariat SF; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Sawczuk I; Serretta V; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Wians F; Roehrborn CG; Lotan Y; Perrotte P; Benayoun S; Marberger MJ; Karakiewicz PI
J Urol; 2005 May; 173(5):1518-25. PubMed ID: 15821471
[TBL] [Abstract][Full Text] [Related]
38. Voided urinary cytology in bladder cancer: is it time to review the indications?
Talwar R; Sinha T; Karan SC; Doddamani D; Sandhu A; Sethi GS; Srivastava A; Narang V; Agarwal A; Adhlakha N
Urology; 2007 Aug; 70(2):267-71. PubMed ID: 17826487
[TBL] [Abstract][Full Text] [Related]
39. Significance of urinary tissue polypeptide specific antigen (TPS) determination in patients with urothelial carcinoma.
Yao WJ; Chang CJ; Chan SH; Chow NH; Cheng HL; Tzai TS; Lin SN
Anticancer Res; 1995; 15(6B):2819-23. PubMed ID: 8669871
[TBL] [Abstract][Full Text] [Related]
40. Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma.
Bian W; Xu Z
Int J Urol; 2007 Feb; 14(2):108-11. PubMed ID: 17302565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
